Daniel J. Lewis

Daniel J. Lewis

Auto-generated profile, based on publicly available information

Daniel J. Lewis

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Clinics in Dermatology
Verified
Journal Article
Closed access
DLDaniel J. Lewis
Daniel J. Lewis
WCWarren H. Chan
Warren H. Chan
THTiffany Hinojosa
Tiffany Hinojosa
SHSylvia Hsu
Sylvia Hsu
Steven R. FeldmanSteven R. Feldman
Steven R. Feldman

29 August 2018 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
SHSimo Huang
Simo Huang
JWJulie H. Wu
Julie H. Wu
DLDaniel J. Lewis
Daniel J. Lewis
PRPeter L. Rady
Peter L. Rady
STStephen Tyring
Stephen Tyring

1 December 2017 in JAMA Dermatology
Verified
Journal Article
Closed access
PDF file
DLDaniel J. Lewis
Daniel J. Lewis
RTRakhshandra Talpur
Rakhshandra Talpur
AHAuris O. Huen
Auris O. Huen
MTMichael T. Tetzlaff
Michael T. Tetzlaff
MDMadeleine Duvic
Madeleine Duvic
Importance Brentuximab vedotin is a monomethyl auristatin E–conjugated monoclonal antibody directed against CD30. It represents a potential treatment for the CD30+lymphoproliferative disorder lymphomatoid papulosis (LyP), which currently has no approved treatment. Objective To assess the efficacy and safety of brentuximab vedotin for the treatment of LyP. Design, Setting, and Participants In this study conducted at The University of Texas MD Anderson Cancer Center from May 10, 2011, to March 31, 2017, a total of 12 patients with LyP received brentuximab vedotin. All patients were 18 years or older with a diagnosis of LyP and were also required to have scarring, more than 10 lesions, or active lesions on the face, hands, or feet. Nine patients were enrolled in a physician-initiated, open-label, single-center, phase 2 clinical trial of brentuximab vedotin for CD30+cutaneous T-cell lymphomas and LyP from 2011 to 2013. Three patients were later treated outside of the trial from 2013 to 2017. Five patients continued to be followed up as of March 2017. Interventions Intravenous brentuximab vedotin 1.8 mg/kg infused over 30 minutes every 21 days. Main Outcomes and Measures The primary end point was the overall response rate. Complete response was defined as zero lesions, and partial response was defined as a 50% or greater reduction in lesion count from baseline. A relapse was defined as loss of partial response. Results All 12 patients (8 men and 4 women; median age, 46 years) responded to brentuximab vedotin, and 7 exhibited a complete response. Time to response was 3 weeks in all patients. The median duration of response was 20 weeks (range, 6-103 weeks). For 5 patients who relapsed, the median time to relapse was 12 weeks (range, 6-41 weeks). One patient who relapsed was retreated and has remained in partial response for more than 23 months. Grade 1 to 2 neuropathy occurred in 10 patients but resolved in 5. Adverse events of grade 3 or higher were neutropenia (n = 2) and dizziness/vertigo (n = 1). Three patients withdrew owing to adverse events. Conclusions and Relevance Brentuximab vedotin is effective in treating LyP (overall response rate, 100%; complete response rate, 58%), but its use should be reserved for patients with truly severe and refractory LyP. More work is needed to optimize its dosing to minimize adverse events, such as peripheral neuropathy. Trial Registration clinicaltrials.gov Identifier:NCT01352520

28 October 2022 in Dermatologic Clinics
Verified
Journal Article
Closed access
DLDaniel J. Lewis
Daniel J. Lewis
JSJoseph F. Sobanko
Joseph F. Sobanko
JEJeremy R. Etzkorn
Jeremy R. Etzkorn
TSThuzar M. Shin
Thuzar M. Shin
CGCerrene N. Giordano
Cerrene N. Giordano
HHH. William Higgins
H. William Higgins

18 May 2018 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
DLDaniel J. Lewis
Daniel J. Lewis
SHSimo Huang
Simo Huang
Madeleine DuvicMadeleine Duvic
Madeleine Duvic

2 June 2020 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
DLDaniel J. Lewis
Daniel J. Lewis
ARAlain H. Rook
Alain H. Rook
Introduction: Advanced mycosis fungoides (MF) and Sezary syndrome (SS) are forms of cutaneous T-cell lymphoma characterized by a poor prognosis. Treatments are associated with high rates of relapse, and thus there exists an unmet medical need for new, improved therapies. Mogamulizumab is a novel defucosylated monoclonal antibody targeting C-C chemokine receptor 4 that eradicates malignant cells via antibody-dependent cellular cytotoxicity (ADCC). Areas covered: Phase I-III clinical trials involving mogamulizumab demonstrated its significant efficacy and tolerability. In the phase III MAVORIC study, mogamulizumab exhibited greater efficacy than vorinostat (response rate, 28% versus 5%; median progression-free survival, 7.7 versus 3.1 months, respectively) for advanced, relapsed/refractory MF/SS. Responses were durable (median, 14.1 months), and response rates were highest in SS (37%) and within the blood compartment (68%). Common adverse events include infusion reactions and drug eruptions. The drug also increases the risk of immune-mediated complications such as autoimmune disease and acute graft-versus-host disease following transplantation. Expert opinion: Mogamulizumab represents a valuable therapy for advanced MF/SS as it can produce prolonged responses, particularly within the peripheral blood. Since it eliminates malignant T cells via ADCC, combining mogamulizumab with immunotherapeutic agents such as interferons, interleukin-12, and Toll-like receptor agonists may further enhance its efficacy.